Jazz Pharma (JAZZ) Raises FY12 Outlook
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $244.54 -2.61%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
CHA, EDXC, YAYO, More
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
CHA, EDXC, YAYO, More
Join SI Premium – FREE
Jazz Pharma (Nasdaq: JAZZ) raised its FY12 EPS guidance to $4.25-$4.40 on sales of $500-$510 million. The Street is currently looking for FY12 EPS of $4.45 on sales of $516.75 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $310 at Needham
- Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
- Lucky Strike Entertainment Corporation (LUCK) reported Q2 Revenue ; Offers Guidance
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
